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An in silico approach to analyze 
HCV genotype‑specific 
binding‑site variation and its effect 
on drug–protein interaction
Ramsha Khalid1, Muhammad Faraz Anwar2, Muhammad Aanish Raees3, Sadaf Naeem1, 
Syed Hani Abidi 2* & Syed Ali4*
Genotype variation in viruses can affect the response of antiviral treatment. Several studies have 
established approaches to determine genotype‑specific variations; however, analyses to determine 
the effect of these variations on drug–protein interactions remain unraveled. We present an in‑silico 
approach to explore genotype‑specific variations and their effect on drug–protein interaction. We 
have used HCV NS3 helicase and fluoroquinolones as a model for drug–protein interaction and have 
investigated the effect of amino acid variations in HCV NS3 of genotype 1a, 1b, 2b and 3a on NS3‑
fluoroquinolone interaction. We retrieved 687, 667, 101 and 248 nucleotide sequences of HCV NS3 
genotypes 1a, 1b, 2b, and 3a, respectively, and translated these into amino acid sequences and used 
for genotype variation analysis, and also to construct 3D protein models for 2b and 3a genotypes. For 
1a and 1b, crystal structures were used. Drug–protein interactions were determined using molecular 
docking analyses. Our results revealed that individual genotype‑specific HCV NS3 showed substantial 
sequence heterogeneity that resulted in variations in docking interactions. We believe that our 
approach can be extrapolated to include other viruses to study the clinical significance of genotype‑
specific variations in drug–protein interactions.
Genetic variability in the viral population can greatly accelerate the rate of viral evolution in response to dif-
ferent selection  pressures1,2. Therefore, the characterization of genomic variations in viral variants is essential 
to understand various aspects of evolution, persistence, epidemiology, immune escape, and development of 
antiviral drug  resistance1–4. Additionally, this analysis can identify crucial variations/mutations associated with 
variability in antiviral treatment response.
Hepatitis C virus (HCV) can serve as a model to study genotype-specific mutations as the clinical significance 
of HCV genotypes in treatment response is well  established5. Studies have suggested that genetic variability in 
HCV genotypes can greatly affect T-cell mediated immune  response6,7. Furthermore, the sequence heterogene-
ity in the HCV genome leads to the generation of HCV genotype-specific epitopes that can potentially evade 
immune  surveillance6,7. Genotypic variation is also known to play a role in determining the course of disease 
progression and antiviral  response6. In the recent past, the combination of pegylated interferon-alpha and a 
nucleotide analog ribavirin-based regimen was the standard care of treatment for HCV infection. HCV genotype 
1 was considered to be the most challenging genotype to treat with this regimen. This regimen gave sustained 
virologic responses (SVRs) in 40%-50% of HCV genotype 1 infected patients as compared to 75%-80% in HCV 
genotype 2 and 3 infected  patients5.
In this paper, we present an in-silico approach to explore genotype-specific amino acid variations and their 
effect on drug–protein interaction. In our study, HCV NS3 helicase was used as a model drug target whereas 
fluoroquinolones were used as model drugs. HCV NS3 is a multifunctional enzyme that belongs to DExH Box 
RNA helicases of superfamily 2 and exhibits NTP-mediated nucleic acid unwinding activity. NS3 plays a pivotal 
role in HCV biology particularly in the viral replicative cycle, viral assembly, persistence, and  pathogenesis8–10. 
Additionally, NS3 is well characterized in terms of structure, domains, functionally active amino acid residues, 
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nucleic acid interaction and unwinding mechanism. However, the genotype-specific variations in HCV NS3 
and their effect on NS3 structure, and subsequently on drug–protein interactions, are relatively unexplored.
Fluoroquinolones are broad-spectrum antibiotics that target DNA gyrase and topoisomerase IV—bacterial 
enzymes involved in DNA replication—forming an irreversible drug–protein-nucleic acid  complex11. Previ-
ously reported studies from our group and others have demonstrated that fluoroquinolones actively inhibit 
HCV replication by targeting viral protein NS3helicase. Since bacterial gyrase and viral helicase are functionally 
homologous; it has been hypothesized that fluoroquinolones inhibit viral helicases in a similar  fashion12–15. To 
explore how genotype-specific variations in HCV NS3 might affect the inhibition of its activity by fluoroqui-
nolones, we have investigated the effect of active site residue variations in HCV genotype 1a, 1b, 2b and 3a on 
NS3-fluoroquinolone interactions.
Results
Inter‑genotype sequence comparison. To explore the inter-genotype sequence similarity in NS3 pro-
tein, multiple sequence alignment was performed using NS3 sequences from HCV genotypes 1a, 1b, 2b, and 
3a, followed by the construction of sequence identity matrix. The analysis was carried out in two different ways, 
one using the full-length protein sequence (Table 1a) and the other employing only the fluoroquinolone bind-
ing region sequence (Table  1b). Both the approaches revealed an overall high degree of sequence similarity 
between NS3 helicases from genotypes 1a and 1b, i.e. 93.4% in the full-length protein sequence (Table 1a) and 
94% in the fluoroquinolone binding region site (Table 1b). When compared to genotypes 2b and 3a, genotypes 
1a and 1b revealed sequence identity scores ranging from 81.5–82.9% for full length protein sequence (Table 1a) 
and 83.3–88.1% for fluoroquinolone binding region site (Table 1b). Between genotypes 2b and 3a, sequence 
identity of 80.8% and 85.3% were observed, respectively, for full length and fluoroquinolone binding region site 
sequences (Table 1a and b).
Before inter-genotype mutation analysis (Fig. 1A), the genotype-specific consensus sequences were com-
pared with the available reference sequences. The analysis revealed that the consensus and reference sequences 
were identical, with exception of 1–2 sites (Fig. 1B), validating that the consensus sequences used in our study 
represent ‘true’ genotype-specific sequences.
Mutational analysis of the fluoroquinolone binding region from genotypes 1a, 1b, 2b, and 3a, revealed a 
total of 90 and 73 variable sites, where genotype 3a revealed the most genotype-specific variations (Figs. 1A and 
2). Fluoroquinolone binding region of NS3 sequences contained 33 conservative, 12 semi- conservative and 
28 non- conservative amino acid substitutions amongst the four genotypes. Out of these, 3 positions namely 
343 T/N/H/S (in genotype 1a/1b/2b/3a), 358V/T/F/L and 553S/A/G/Q showed variable amino acids across all 
genotypes (Figs. 1A and 2).
Our analysis revealed a high degree of conservation in helicase signature motifs across the four genotypes, 
except for motif V and motif VI (Fig. 1A), wherein certain genotypes a single amino acid substitution was 
observed (Fig. 1A). In motif V, F418Y variation was noted, where Y variant was found in genotype 2b; simi-
larly, in motif VI, T459S was observed in genotype 1b, 2b, 3a, while K469R was observed in genotype 1b, 2b, 3a 
(Figs. 1A and 2). As mentioned in Methods, for this and other analyses 1A1V was used as the reference sequence.
Validation of 3D structures and docking strategy and genotype‑specific variations in NS3‑fluo‑
roquinolone interactions. Before docking the NS3 structures were verified and validated using Verify 3D, 
GROMACS, and Ramachandran plot analysis. Structures constructed from three different tools were compara-
ble, where structures constructed using Phyre 2 and Swiss-Model gave the lowest RMSD values of 0.41 and 0.0, 
respectively for genotype 2b and 0.42, and 0.07 for genotype 3a, respectively, when compared to the template 
structure. CPH tool has higher RMSD values of 1.55 and 1.53 for genotypes 2b and 3a, respectively, when com-
pared to the template structures. All structures passed the 3D verification (performed using Verify 3D software) 
as at least 80% of the amino acids have scored >  = 0.2 in the 3D/1D profile. Similarly, the structures were valid on 
the Ramachandran plot as most of the amino acids were under the permissible regions (Supplementary Fig. 1). 
Table 1.  Identity matrix of amino acid sequences of NS3 HCV of genotype 1a, 1b, 2b and 3a: Sequence 
identity was estimated in full length and fluoroquinolone binding region sequences by constructing an ID 
matrix using the ‘BioEdit’ software. The identity scores are expressed as percentages.
HCV genotypes 1a 1b 2b 3a
Full length
1a – 93.4 82.1 81.5
1b 93.4 – 82.9 82.8
2b 82.1 82.9 – 80.8
3a 81.5 82.8 80.8 –
Fluoroquinolone binding region
1a – 94.0 87.3 83.3
1b 94.0 – 88.1 85
2b 87.3 88.1 – 85.3
3a 83.3 85.0 85.3 –
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Figure 1.  Sequence alignment of HCV NS3 genotypes 1a, 1b, 2b, 3a: (A) Multiple sequence alignment was 
performed employing ‘Clustal W’ using the amino acid sequence in the fluoroquinolone binding region 
(Pro230-Cys584). The fluoroquinolone binding region is highlighted in red font. Conservative helicase 
motifs (I-VI) are indicated by black lines on top of the alignment. Conservative, semi-conservative and non- 
conservative amino acid variations are marked in blue, yellow and grey colors, respectively. (B) Pairwise 
sequence alignment was performed employing ‘Clustal W’ using 1a, 1b, 2b, 3a amino acid sequence and their 
respective reference sequences 1a (PDB ID:1A1V), 1B (PDBid:1CU1), 2B (UNIPROT ID: Q9DHD6) and 3A 
(UNIPROT ID: Q81495).
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Based on the lowest RMSD values, overall better quality (based on Verify 3D and Ramachandran plot assess-
ment) models developed using Swiss-Model was used in further analyses (Fig. 3). The structural comparison 
revealed the structures of the four genotypes to be quite similar (Fig. 3). The RMSD values between structures 
of genotype 1a–1b, 1a–2b, 1a–3a, 1b–2b, 1b–3a, 2b–3a were found to be 0.01, 0.03, 0.03, 0.03, 0.03, and 0.04, 
respectively, suggesting strong homology between the NS3 structures from the four genotypes.
Similarly, validation of the docking approach was done by performing blind docking (assuming drug bind-
ing site to be anywhere on the protein) on two previously reported complexes of NS3 bound to inhibitors, one a 
natural analog and other inhibitor ITMN-3479. Our results revealed that for both the models Molegro predicted 
the exact binding site/pose and gave the similar drug–protein interaction (for natural analog: Asp 454, Gln 481 
and Cys 431; for ITMN-3479: Gly255, Thr269, Trp501) as reported for the reference models (Fig. 4 A and B).
To investigate the effect of genotype-specific variations on NS3-fluoroquinolones interactions, molecular 
docking simulations were performed. Eight fluoroquinolones were docked individually on the consensus NS3 
helicase structure constructed for each genotype.
Comparative analysis of the drug–protein interactions and binding poses revealed that almost all fluoroqui-
nolones interacted with NS3 from all genotypes essentially in the same binding pocket, comprising amino acids 
Figure 2.  Structure of HCV NS3 with genotype-specific amino acid substitutions across HCV variants 1a, 
1b, 2b, and 3a. Ribbon Diagram of (A) front view, and (B) posterior view of NS3 reference structure (PDB ID: 
1A1V). Within the fluoroquinolone binding region (P230-C584), amino acid residues variable across HCV 
genotypes are highlighted in yellow color, while the substrate-binding site, R393-W501, is shaded dark blue. 
Amino acids of genotype1a, 1b, 2b, and 3a are shown in the blue, red, green and purple font, respectively. A total 
of 73 amino acid variations were observed. To improve visualization, both the front and posterior views of NS3 
were examined. Amino acids that were found to interact with fluoroquinolones are shown in orange boxes.
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Figure 3.  Structures of NS3 HCV: Structures of HCV NS3 used in the study are given. Sutures for (A) 1a (PDB 
ID: 1A1V) and (B) 1B (PDBid:1CU1) were retrieved from the PDB database, while structures of (C) 2b and (D) 
3a were constructed using homology modeling approach using CPH model, Swiss model, and Phyre 2 software. 
Models shown in this figure were constructed using Swiss model.
Figure 4.  Validation of Docking strategy: Docking strategy was validated by re-docking the two previously 
published ligands (A) natural analog and (B) inhibitor ITMN-3479 on their respective ligands. (A) and (B) 
Poses of ligands bound to their receptors are shown, while tables at the bottom show amino acid interactions 
reported for each ligand and observed in our study. Ligand is shown in red, while protein is shown in dark grey 
color.
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Pro230-Cys584 (Figs. 5 and 6; Table 2; Supplementary Table 2). However, in some of the poses, fluoroquinolo-
nes, such as Balofloxacin, Ciprofloxacin, and Levofloxacin, etc., exhibited a more scattered interacted with NS3 
from genotype 1b (Fig. 6). No amino acid was found to form interactions with all fluoroquinolones, however, 
certain amino acids appeared to be crucial in the drug–protein interaction (Table 2; Supplementary Table 2). 
The amino acid residues that frequently made interactions with most fluoroquinolones were Arg481, Asp454, 
His293, and Gln434 (Table 2). Position 295 in all genotypes appeared to be important in drug–protein interac-
tion as amino acids at this position, despite inter-genotype variation (genotypes 1a and 1b: Thr295; genotype 2b: 
Val295; genotype 3a: Gln295), interacted with almost all fluoroquinolones (Figs. 5 and 6; Table 2). In addition to 
position 295, certain genotype-specific residues commonly interacted with each of the fluoroquinolones; these 
residues include Leu451, Ser457, Asp454, and Arg481 in genotype 1a, and Glu493, and Ser297 in 1b. In contrast, 
for genotypes 2b and 3a, different residues were involved in forming interactions with different fluroquinolones 
(Figs. 5 and 6; Table 2; Supplementary Table 2).
Analysis of the docking scores between NS3 (from different genotype) and different fluroquinolone showed 
the docking scores for Balofloxacin-NS3 ranged from − 98 to − 111; Ciprofloxacin-NS3 ranged from − 103 to 
− 114; Enrofloxacin-NS3 ranged from − 121 to − 100; Lomefloxacin-NS3 ranged from − 90 to − 101; Levofloxacin-
NS3 ranged from − 90 to − 115; Ofloxacin-NS3 ranged from − 88 to − 106; Sparfloxacin-NS3 ranged from − 87 
to − 104; and Pefloxacin-NS3 ranged from − 87 to − 109 (Table 3).
Discussion
In the current study, we present an in-silico approach to assess the effect of genotype-specific amino acid vari-
ations on protein folding and structural architecture and its interaction with the drugs. Our strategy involved 
computational analysis of NS3 helicase sequence and structures followed by molecular docking of fluoroqui-
nolones on genotype-specific NS3 structures.
In the past era, a substantial number of studies explored the genetic heterogeneity of viral genotypes and 
its correlation with various aspects of the viral life cycle, including replication, and pathogenesis. Additionally, 
efforts have been made to unravel inter-genotype clinical and serological variations, functional differences in viral 
proteins and their effect on host immune system, generation of escape variants and viral epitopes, and on antiviral 
treatment  response16–20. For example, the study conducted by Kaneez et al. showed amino acid variability in HCV 
NS3 1 and 3a and its impact on the structural architecture of the protein. The study also emphasized on the func-
tionally active and conservative residues across selected HCV genotypes. To do so, several bioinformatics-based 
approaches and computational methods were employed. They reported that genotype-specific variations affected 
the structural architecture of  NS321. Similarly, Ahmed et al.22 established the impact of sequence heterogeneity 
within NS5A and core regions on the response to pegylated interferon/ribavirin (PEG‐IFN/RBV) therapy against 
HCV. The results showed a significant association between heterogeneity in IFN/RBV resistance‐determining 
region IRRDR of NS5A and SVR, indicating that genetic heterogeneity in IRRDR can potentially serve as a 
predictor for SVR in HCV-infected patients treated with PEG-IFN/RBV combinatorial  therapy22.
Another study published by Di Maio et al. implemented an in-silico approach to identify NS5B genetic vari-
ability in HCV genotypes and its potential effect on the genetic barrier for drug resistance (nucleoside inhibitors 
(NI)and non-nucleoside inhibitors(NNI))23. The impact of these mutations was analyzed via docking of sofosbu-
vir with the NS5B protein of HCV genotypes. This study suggested that HCV sequence variability in NS5Bcan 
potentially alter the efficacy of NS5B  inhibitors23.
The approach we have used here has the advantage that it analyzes the effect of naturally occurring genotype-
specific amino acid variations on drug–protein interactions in the absence of drug-induced selection pressure. 
This method allowed us to correlate genotype-specific sequence heterogeneity with its influence on protein’s 
structural architecture, and with its effect on variable interactions with selected drugs. This approach can be 
extended to other viruses to study the clinical significance of genotype-specific sequence variations that influ-
ence drug–protein interactions.
In our study, sequence to structure comparison identified the following genotype-specific substitutions: 
Y241F in genotype 3a (Motif Y), F418Y in genotype 2b (Motif V), and S459T in genotype 1a (Motif VI), whereas 
V256N in genotype 3a, S294A in genotype 3a, T295V/Q in genotypes 2b and 3a, A297S in genotype 1b, S299T 
in genotype 1b and 2b, T430V in genotype 2b and 3a, E555D/L in genotype 2b and 3a, P558A/S in genotype 2b 
and 3a and Q580V/E in genotype 2b and 3a (Figs. 1 and 2).
In the previous structural–functional studies of NS3 HCV, it has been proposed that the residues that play 
a critical role in NTP and substrate binding are found in the conserved helicase motifs: Motif I/Walker A 
(207′-GSGKSTK-213′), Ia (223′-YKVLVLNPSVA-233′), Walker B/Motif II (290′-DECH-293′), III (319′-VLA-
TATPP-326′), IV (365′-LIFCHSKKK-373′), V (410′-ATDALMTGYTGDF-422′), and VI (456′-VSRSQRRG RTG 
R-467′)(Fig. 1)21,24,25. These helicase signature motifs are oriented in such a manner that their spatial arrangement 
forms the lining of NTP and substrate binding pocket, located in the cleft between domains 1 and  225,26. Motif Y 
(Y241) is a characteristic motif of NS3 HCV located between motifs 1a and 1b. Tyrosine241 plays an important 
role in stacking the adenine base of ADP in correspondence with  T41926. In addition to these, amino acids at posi-
tions 256V/V/V/N, 294S/S/S/A, 295T/T/V/Q, 297A/S/A/A, 299S/T/T/S, 430T/T/V/V, 555E/D/D/L, 558P/P/A/S 
and 580Q/Q/V/E exhibited genotype-specific variation. These amino acids form the entry side of ssRNA/DNA21.
In light of our observations, we speculate that A240S in genotype 3a, A431C in genotype 1a, T433E in geno-
type 3a, T435I/Y in genotype 2b and 3a, T445S in genotype 3a, E447T in genotype 2b, T449Q/R in genotype 
2b and 3a, A500S in genotype 3a and F557L in genotype 1a might be of functional importance. These amino 
acids are present in the vicinity of the residues involved in the catalytic center and/or substrate binding loop, 
and therefore, can influence nucleic acid binding and NS3 catalytic activity. Residue Y241 is crucial for form-
ing interactions with the adenine base of  ADP21,26. In genotype 3a, we observed substitutions at both positions 
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Figure 5.  Molecular docking simulation of HCV NS3 with fluoroquinolones constructed for four HCV 
genotypes. HCV NS3 protein each from genotype (A) 1a, (B) 1b, (C) 2b, and (D) 3a, was docked with the batch of 
8 fluoroquinolones using the Molegro software. In the left panels, a cluster of 8 fluoroquinolones is shown docked 
into the NS3 binding site, where structures of genotype 1a, 1b, 2b, and 3a are represented with blue, red, green and 
purple, respectively. The right panels give schematic representations of the fluoroquinolone-interacting amino 
acids. Binding of fluoroquinolones with each of the amino acids is indicated with color-coded squares where red, 
purple, light green, dark green, yellow, blue, orange and pink represents Ciprofloxacin, Lomefloxacin, Enrofloxacin, 
Levofloxacin, Ofloxacin, Pefloxacin, Sparfloxacin, and Balofloxacin, respectively. The grey dashed lines show amino 
acids located in the back of the fluoroquinolone cluster.
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Figure 6.  Docking poses of HCV genotype-specific NS3 models interacting with different fluoroquinolones: 
The structures of NS3 from genotype 1a, genotype 1b, genotype 2b, and genotype 3a are shown in blue, 
purple, green, and grey, respectively. The docked poses of ligands (top 10 poses) are shown in the following 
order: (1) Ciprofloxacin, (2) Levofloxacin, (3) Ofloxacin, (4) Pefloxacin, (5) Balofloxacin, (6) Enrofloxacin, (7) 
Sparfloxacin, and (8) Lomefloxacin.
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Drugs 1a 1b 2b 3a
Balofloxacin
– – – ASN229
– – PRO230 PRO230
– – GLU291 GLU291
HIS293 HIS293 HIS293 HIS293
THR295 THR295 VAL295 GLN295
– ASP296 ASP296 ASP296
– SER297 – –
– THR298 – –
ARG393 – – ARG393
THR411 – – –
– – ASP412 –
– – MET415 –
VAL432 – VAL432 –
– – – GLU433
– GLN434 GLN434 GLN434
LEU451 – – –
PRO452 – – –
– ASP454 – –
SER457 – – –
– – – GLN460
– – – ARG464
– – – ARG467
ARG481 ARG481 ARG481 –
GLY484 GLY484 – –
MET485 MET485 – –
– – – ASP487
– GLU493 – –
– GLY554 – –
Ciprofloxacin
– – – THR206
– – ASN229 –
– GLU291 – –
HIS293 HIS293 – –
THR295 – VAL295 GLN295
ASP296 ASP296 – ASP296
– SER297 – –
– – – ARG393
THR411 – – THR411
– – ASP412 –
ALA413 – – –
– – MET415 MET415
VAL432 VAL432 – –
– THR433 THR433 –
– GLN434 GLN434 GLN434
LEU451 – – –
PRO452 – PRO452 –
ASP454 – – –
VAL456 – – –
SER457 – – –
– GLN460 GLN460 GLN460
ARG461 – – –
– – – ARG467
ARG481 – – –
GLY484 GLY484 – –
MET485 MET485 – –
– – ASP487 ASP487
– – GLU493 –
– TRP501 – –
– ASP555 – –
– ASN556 – –
– – PHE557 –
Continued
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Drugs 1a 1b 2b 3a
Enrofloxacin
– – – ASN229
– – – SER231
– – GLU291 GLU291
– HIS293 – –
THR295 THR295 VAL295 –
– SER297 – –
– THR298 – –
THR411 – – –
– – MET415 MET415
– – VAL432 –
– – – GLU433
– – – GLN434
LEU451 – – –
PRO452 – – –
ASP454 ASP454 ASP454 ASP454
SER457 – – SER457
GLN460 GLN460 GLN460 GLN460
ARG464 – – –
ARG481 ARG481 ARG481 ARG481
– GLY484 – –
MET485 MET485 – –
ASP487 – – ASP487
– GLU493 – –
– TRP501 – –
– TYR502 – –
– ASN556 – –
Lomifloxacin
– – – PRO230
– – GLU291 –
HIS293 HIS293 – HIS293
THR295 – VAL295 GLN295
– – ASP296 ASP296
– – – ALA297
– HIS369 – –
THR411 – – –
– ASP412 ASP412 –
– MET415 MET415 –
– – – THR416
VAL432 – – –
THR433 – THR433 –
– GLN434 GLN434 –
LEU451 – – –
– ASP454 ASP454 ASP454
SER457 – – –
– – – GLN460
ARG461 – – –
– PRO482 – –
SER483 – – –
GLY484 – – –
MET485 MET485 – –
ARG481 ARG481 ARG481 –
– ASP487 ASP487 ASP487
– – GLU493 –
– – – ASP496
– – – TRP501
– – – SER558
Continued
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Drugs 1a 1b 2b 3a
Levofloxacin
– – – ASN229
– – – SER231
– – GLU291 GLU291
HIS293 HIS293 – –
THR295 THR295 VAL295 GLN295
– – – ASP296
– – – ALA297
HIS369 – – –
ASP412 – – ASP412
– – MET415 –
VAL432 – – –
– – THR433 GLU433
– GLN434 GLN434 –
LEU451 – – –
ASP454 – ASP454 ASP454
– ASP555 – –
SER457 – – SER457
GLN460 GLN460 – –
ARG461 – – –
ARG481 ARG481 ARG481 ARG481
GLY484 GLY484 – –
MET485 MET485 – –
– – – ASP487
– – – TRP501
– – – ASN556
– PHE557 – PHE557
– – – SER558
Ofloxacin
– – ASN229 ASN229
– HIS293 – HIS293
SER294 – – –
THR295 THR295 VAL295 GLN295
– ASP296 – –
– – – ALA297
THR411 – –
ASP412 ASP412 – –
– MET415 MET415 MET415
– THR416 – –
VAL432 VAL432 – –
– – THR433 –
– – GLN434 GLN434
LEU451 – – –
PRO452 – – –
ASP454 – – –
SER457 – – –
QLN460 – – GLN460
– ARG461 – –
ARG464 – – ARG464
– – – ARG467
ARG481 – – –
– PRO482 – –
– GLY484 – –
– MET485 – –
ASP487 – ASP487 ASP487
– – – GLU493
Continued
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Drugs 1a 1b 2b 3a
Sparfloxacin
– – – PRO230
– THR269 – –
– GLY271 – –
– – GLU291 GLU291
HIS293 HIS293 – HIS293
THR295 – VAL295 GLN295
ASP296 – ASP296 –
– SER297 – –
– THR298 – –
ASP412 – ASP412 ASP412
– – MET415 MET415
– THR416 – –
VAL432 – VAL432 –
THR433 – THR433 –
GLN434 GLN434 GLN434 GLN434
LEU451 – – –
– PRO452 –
– – ASP454 ASP454
SER457 – – –
GLN460 – – GLN460
ARG464 – – –
ARG467 – – ARG467
ARG481 ARG481 ARG481 ARG481
– PRO482 – –
GLY484 – – –
MET485 MET485 MET485 –
ASP487 – ASP487 ASP487
– GLU493 – GLU493
– TYR502 – –
– – – ASN556
Pefloxacin
– – ASN229 ASN229
– – – SER231
– – – GLU291
HIS293 HIS293 HIS293 HIS293
THR295 THR295 VAL295 GLN295
ASP296 ASP296 – –
– SER297 ALA297 –
– – – THR298
HIS369 – – –
LYS371 – – –
THR411 – – –
– ASP412 – –
– – MET415 MET415
THR416 – – –
VAL432 – – –
– GLN434 GLN434 GLN434
LEU451 – – –
ASP454 – ASP454 ASP454
SER457 – – –
GLN460 GLN460 – GLN460
– – – ARG464
ARG481 – ARG481 –
– GLY484 – –
MET485 MET485 MET485 –
ASP487 – ASP487 ASP487
– SER489 – –
– GLU493 – –
– TRP501 – –
– ASP555 – –
Table 2.  HCV genotype 1a, 1b, 2b and 3a NS3 amino acids residues interacting with Fluoroquinolones: 
Molegro Virtual Docker software was employed to dock the panel of 8 fluoroquinolones (Sparfloxacin, 
balofloxacin, Enrofloxacin, Ofloxacin, Pefloxacin, Lomefloxacin, Levofloxacin, and Ciprofloxacin) on each 
of the four NS3 helicases from different HCV genotypes. The table shows amino acid residues (bold) in the 
fluoroquinolone binding region of NS3 helicase from different genotypes that formed interactions with the 
fluoroquinolones. Absence of a reside in genotype(s) is indicated by ‘–’.
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240 and 241 simultaneously, while the Tyrosine241 was replaced with phenylalanine, alanine at position 240 
that was substituted with serine. These substitutions concurrently can affect the binding of ATP molecule and 
subsequently the helicase activity due to changes in the electrostatic environment of the binding site. In close 
vicinity of Walker B Motif, lie residues 294 and 295. In this motif, H293 is of prime importance and is implicated 
in the coupling of ATPase and helicase  activity21. Amino acid 294 and 295 are not only found in the proximity 
H293 but are also present at the entry side of the substrate. Therefore, substitutions at these positions, such as 
S294A and T295V/Q (Figs. 1 and 2), might not only influence entry and binding orientation of ssRNA/DNA 
but may also affect NTP binding and hydrolysis. Motif V corresponds to the coordination of ATP and substrate 
 binding21,26,27. We observed a substitution of amino acid F418Y, adjacent to the functionally important residue 
419, involved in NTP binding and  catalysis21. Here, we speculate little or no effect on the activity because the 
amino acid change was conservative. Residues 431C/C/A/A, 433T/T/T/E, 435T/T/I/Y, 445T/T/T/S, 447E/E/T/E, 
449T/T/Q/R, 500A/A/A/S, 557L/F/F/F may play either a direct or indirect role in ssDNA/RNA interaction and 
unwinding. This leads us to speculate that genotype-specific variations in these amino acids might influence 
substrate interaction and helicase activity.
A characteristic structural feature of NS3 HCV is a β-hairpin spanning the amino acids 430–452. This hair-
pin consists of two conserved phenylalanine residues F438 and F444. Residues V432 and T450 in the hairpin 
are known to be involved in nucleic acid  interactions28. V432 intercalates between the DNA bases, stacks the 
nucleotide bases at 5′ terminal, and locks the enzyme in position, whereas T450 is involved in ssDNA binding 
to the nucleic acid pocket of the NS3  helicase28. F438 and F444 are responsible for the release ssDNA upon ATP 
 binding28. It may be suggested that substitutions in the vicinity of these two residues, at positions 430T/T/V/V, 
431C/C/A/A, 433T/T/T/E, 435T/T/I/Y, 445T/T/T/S, 447E/E/T/E, 449T/T/Q/R and 451L/V/V/A can alter the 
flexibility of the loop and subsequently might affect substrate interaction. Q460, a conserved residue of helicase 
Motif VI, plays a key role in ATP binding and coupling ATP hydrolysis with helicase  translocation26. W501 is a 
critical residue for nucleic acid  binding26.
To gain insights in drug–protein binding pattern across the HCV genotypes; molecular docking simulations 
were performed with NS3 protein models of each candidate genotype against a batch of 8 fluoroquinolones 
(Sparfloxacin, Ciprofloxacin, Balofloxacin, Levofloxacin, Lomefloxacin, Enrofloxacin, Pefloxacin, and Ofloxa-
cin) previously shown to exhibit inhibitory potential against HCV NS3 helicase under in vitro  conditions12. In 
our analysis, it was observed that the fluoroquinolones interacted with amino acids that constitute the helicase 
catalytic core via H-bond as well as non-bond interactions (Supplementary Table 2). Several studies have dem-
onstrated that both H-bonds and hydrophobic interactions stabilize the ligands at the target site and assist in 
altering binding affinity and drug  efficacy29. Furthermore, biological activity of the drug increased with increase 
in the number of hydrophobic interactions in the core of drug–target  interface29. The residues that are function-
ally important and were found involved in H-bond as well as non-bond interactions with our drugs are P230, 
S231, T269, K371, R393, W501 and  Y50225,26 (Figs. 5 and 6; Table 2; Supplementary Table 2). Residues S231, 
T269, W501, and Y502 are functionally important as they are known to facilitate the interactions of NS3 with a 
3′ segment of substrate/ssDNA. P230 and S231 are key residues involved in DNA binding. S231 interacts with 
substrate/ssDNA via bridging water molecule, while T269 is thought to be indispensable for helicase activity of 
NS3. K371 and R393, crucial residues of NS3 active site, are involved in substrate binding, where R393 makes 
interactions with the 5′ segment of ssDNA and coordinates in translocation of NS3  helicase25,26; in addition to 
this, K371 participate in stabilizing the interaction with ssDNA/RNA30. W501 stacks the nucleotide bases near 
the 3′ end of the substrate/ssDNA and acts as a bookend along with V432 that defines a central binding  cavity26.
Fluoroquinolones, Sparfloxacin (in genotype 3a), Balofloxacin (in genotype 2b and 3a), and Lomefloxacin 
(in genotype 3a) targeted residue P230 (Fig. 5 and Table 2) that might hinder in substrate binding. Enrofloxa-
cin, Levofloxacin, and Pefloxacin (in genotype 3a) were found to interact with residue S231. Interactions of the 
Enrofloxacin, Levofloxacin, and Pefloxacin with these residues might affect ATP binding and transition as well 
as enzyme–substrate interaction. Likewise, Sparfloxacin (in genotype 1b) targeted T269 (Table 2) that can poten-
tially inhibit substrate binding and subsequently NS3 unwinding activity. R393 is thought to be a key residue that 
makes direct contact with ssDNA/RNA as well as facilitates nucleic acid  unwinding28. Therefore, drugs such as 
Table 3.  Molegro docking score for NS3-Fluoroquinolones interactions: Molegro docking score for top 10 
poses observed for each fluoroquinolone-NS3 (specific to each genotype) interactions are shown. Previously 
determined in vitro IC50 (µM) for each fluoroquinolone, except for Levofloxacin (shown as –) is also given.
Ligand (top 10 poses) IC50 (uM)12
Genotype 1a 
(MolDock score)
Genotype 1b 
(MolDock score)
Genotype 2b 
(MolDock score)
Genotype 3a 
(MolDock score)
Balofloxacin 1.37 − 99 − 105 − 112 − 104
Ciprofloxacin 2.99 − 104 − 115 − 108 − 110
Enrofloxacin 1.15 − 101 − 102 − 107 − 122
Levofloxacin – − 90 − 116 − 106 − 102
Lomefloxacin 1.14 − 96 − 91 − 102 − 99
Ofloxacin 1.47 − 88 − 97 − 107 − 100
Pefloxacin 4.22 − 103 − 87 − 102 − 110
Sparfloxacin 1.22 − 92 − 88 − 104 − 92
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Balofloxacin (in genotype 1a and 3a), Ciprofloxacin (in genotype 3a) targeting residue R393 (Fig. 5 and Table 2) 
can greatly affect substrate binding, NS3 translocation and subsequently nucleic acid unwinding.
W501 is a critical amino acid of substrate binding cleft of NS3 HCV that serves as a bookend residue; stacking 
nucleotide of ssDNA/RNA at 3′ terminal preventing the protein from sliding along the nucleic acid and facilitates 
helicase  translocation26,28. Ciprofloxacin, Pefloxacin and Enrofloxacin (in genotype 1b) and Levofloxacin and 
Lomefloxacin (in genotype 3a) interacted with W501, while most fluoroquinolones with interacted residues in 
their proximity of W501, namely E493 (present in genotypes 1b, 2b, and 3a) (Fig. 5 and Table 2), which might 
cause hindrance in nucleic acid interaction and can potentially inhibit the helicase activity of NS3. Maga et al. 
identified a series of compounds out of which QU663 exhibited a strong binding affinity with NS3. QU663 binds 
to the RNA binding cleft and makes direct contact with residues R393 and  W50131 that are crucial for substrate 
binding and helicase translocation. The present study showed that fluoroquinolones we tested also targeted the 
same crucial residues in the substrate-binding catalytic cleft, namely, W501 and R393 (Fig. 5).
We identify a few limitations of our study. A major limitation of this study was that our analysis was per-
formed entirely in silico. We used two crystal structures (for 1a and 1b) and used a homology modeling approach 
to construct NS3 structures for genotypes 2b and 3a. Homology modeling heavily relies on the identification of 
the correct template, selected based on sequence  identity32. A sequence identity above 50% generally tends to 
generate reliable structures with limited errors in loops and side-chain positing, while structures below 30% can 
have serious folding  errors32. Additionally, regions in the query sequence that share low sequence similarity with 
the template protein, even though the rest of the protein show a high sequence similarity, can lead to erroneous 
folding. We tried reducing this bias/error by using three different homology modeling programs, validating 
and checking constructed structures for various errors and using a template that exhibited excellent similar-
ity with our query sequences. Interestingly, all three programs identified 1A1V as a suitable template sharing 
more than 90% similarly with the sequence, and all three programs gave the same structures. Additionally, our 
structures passed the 3D verification (performed using Verify 3D software) as at least 80% of the amino acids 
have scored >  = 0.2 in the 3D/1D profile. Similarly, the structures were valid on the Ramachandran plot as most 
of the amino acids were under the permissible regions. The other limitation we anticipate is with the molecu-
lar docking approach we used. In absence of experimentally characterized binding sites and experimentally 
derived binding energies, molecular docking analyses can be unreliable and can potentially miss out several 
key residues, present artificial interaction with residues and/or under- or over-estimate the binding  scores33. We 
tried to address this issue by validating our docking approach using two previously reported structures bound 
to the ligand. We adopted a ‘blind docking’ approach, where the binding site of the ligand was not defined. 
Our software predicted the same pose for the ligand and also identified all the residues previously reported for 
the two structures. Another limitation that we identify is use of docking score to rank the poses and selection 
the top pose with highest docking score. Docking programs produce one (or several) different poses for every 
ligand, and further rank different compounds based on their scoring  functions34. Several studies suggest that 
binding energies/scores predicted by the docking might be incorrect, despite the correctly predicted binding 
 pose34. These can be overcome by using more robust approached such as MD simulations followed by WaterMap 
analysis; however, these approaches can be time-consuming and computationally  demanding34. Nonetheless, 
as the experimentally solved structures continue to grow, the boundaries that differentiate between reliable and 
unreliable predictions will narrow and the capacity of the docking tools to predict correct poses/interactions will 
 increase32. However, to gain further insights into the mechanism, site-directed mutagenesis of crucial residues 
followed by functional assays may be employed. These analyses should be supplemented by observations from 
the crystal structures of drug–enzyme complexes.
In conclusion, our approach provides an in-depth analysis of sequence variation in HCV NS3 protein across 
the selected genotypes and identifies active site amino acid residues crucial for drug–protein interactions. This 
approach can help study inter-genotype sequence heterogeneity in viral proteins and its correlation with the 
response to the antiviral treatment regimen.
Methods
Retrieval of HCV NS3 sequences and sequence analysis. A total of 1703 HCV NS3 sequences, 
belonging to genotype 1a, 1b, 2b, and 3a were downloaded in FASTA format from Los Alamos HCV Database 
(https ://hcv.lanl.gov/conte nt/index )35. Other genotypes were not considered because their sequences were not 
present in the database in sufficient numbers to conduct a meaningful analysis. Out of these sequences, 687, 667, 
101 and 248, belonged to, respectively, genotype 1a, 1b, 2b, and 3a. Sequences for each genotype were aligned 
separately and edited using the MEGA 6.0 software, implementing the ClustalW algorithm. The aligned nucleo-
tide sequences were then used to generate consensus sequences for each of the candidate genotypes using the 
advanced ‘Consensus maker’ tool with 0.7 thresholds (i.e. residues represented in ≥ 70% of the sequences were 
used to generate a consensus) (http://www.hiv.lanl.gov/conte nt/seque nce/CONSE NSUS/conse nsus.html). In all 
genotypes, almost all consensus residues/sites were present in 99% of the sequences, with exception of a few sites, 
where consensus residues were present in 70–85% sequences (Supplementary Table 1). The consensus sequences 
of NS3 for genotypes 1a, 1b, 2b, and 3a were subsequently translated to amino acid sequences using the ExPASy 
translate  tool36. Additionally, reference sequences for genotypes 1a, 1b, 2b, and 3a were downloaded in FASTA 
format PDB (genotype 1a: PDBid:1A1V and genotype 1b: PDBid:1CU1) and UniProt (genotype 2b: UniProt 
ID Q9DHD6 and genotype 3a: UniProt ID Q81495) databases. For genotype variation analysis, the genotype 
sequences were aligned with each other using the ClustalW algorithm implemented in MEGA 7  software37. 
Additionally, each genotype consensus sequence was also aligned, using MEGA 7, with its reference sequence to 
compare the difference in consensus sequences and the reference sequences.
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Inter-subtype sequence similarities and differences were determined by constructing a sequence identity 
matrix using ‘Bioedit’  software38. Two ID matrices were constructed: one with a full-length sequence of HCV 
NS3 helicase comprising 623 amino acids, and the other comprising of amino acids spanning Pro230-Cys584 
(termed in this study as fluoroquinolone binding region). This region was selected because fluoroquinolones are 
found to form interactions with different amino acids within this  region39. Additionally, this region also contains 
the previously reported helicase active site, spanning from Arginine393 to  Tryptophan5018,40,41.
Retrieval of HCV helicase structures and protein homology modeling. PDB and UniProt data-
bases were searched for the available genotype-specific NS3 helicase structures and crystal structures were only 
found for genotypes 1a and 1b. These structures (genotype 1a: PDBid:1A1V and genotype 1b: PDBid:1CU1) 
were downloaded on .pdb format. For genotypes 2b and 3a, the Homology Modeling approach was adopted for 
the generation of 3D protein  structures10,42. For accuracy and reliability, 3D models of NS3 were generated using 
three different homology modeling tools, namely the CPH model, the Swiss model and Phyre  243–45. The struc-
tures were visually inspected in Discovery Studio Visualizer version 4.0 (DSV4.0; Dassault Systèmes BIOVIA, 
Discovery Studio Visualizer, version 4.0, San Diego: Dassault Systèmes, 2016; Retrieved from http://accel rys.com/
produ cts/disco very-studi o/), and thereafter saved in PDB format. Subsequently, the structures were verified 
using the Verify 3D tool, while the energy minimization and validation were performed using the GROMACS 
 tool46 and Ramachandran plot analysis implemented in DSV4.0.
Fluoroquinolone structures. In this study, we used a panel of 8 fluoroquinolones, namely Sparfloxacin, 
Ofloxacin, Balofloxacin, Pefloxacin, Levofloxacin, Lomefloxacin, Ciprofloxacin, and Enrofloxacin, that have pre-
viously been reported to effectively inhibit HCV NS3  helicase12. Structures of these drugs were retrieved from 
PubChem Database in 3D SDF  format47. Before docking analysis, SDF structures were converted to PDB format 
using DSV4.0.
Analysis of genotype‑specific fluoroquinolone‑NS3 interactions. Molecular docking simulations 
were performed to analyze the genotype-specific protein–ligand interactions. The docking approach was vali-
dated by performing blind docking (assuming drug binding site to be anywhere on the protein) on two previ-
ously reported complexes of NS3 bound to inhibitors, one a natural analog  M248 and other inhibitor ITMN-3479 
(http://www.rcsb.org/pdb/explo re/litVi ew.do?struc tureI d=3RVB). Molecular docking studies and conforma-
tional analysis were conducted by Molegro Virtual  Docker49 and DSV4.0 software. Molegro Virtual Docker 
binding site was set to default, where the Molegro identifies the binding ligand binding sites in the protein. For 
our analysis, Molegro identified two binding sites, one located in the DNA binding domain, which contained the 
key residues within the active site of NS3, as identified by previous  reports8,40,41, and others in the ATP domain 
of the helicase. The 8 fluoroquinolones were docked individually on each of the four genotype-specific models 
of NS3, into the identified cartesian space. Molecular docking was performed using standard precision protocols 
with default parameters of Molegro Virtual Docker. A total of 2000 interactions were simulated, and out of those 
top 10 poses was selected based on docking energies. Using these poses, analysis of genotype-specific variations 
on NS3-fluoroquinolone binding was carried out. Visualization of docking poses and analysis of drug–protein 
interactions were performed using DSV4.0.
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